| RS2066640120 |
COL4A5
|
Health Risk |
Likely pathogenic |
Alport syndrome, X-linked Alport syndrome |
| RS2066649828 |
MITF
|
Health Risk |
Pathogenic |
— |
| RS2066652447 |
MITF
|
Health Risk |
Pathogenic |
Waardenburg syndrome type 2A, Waardenburg syndrome type 2A |
| RS2066653512 |
ACO2
|
Health Risk |
Pathogenic |
Optic atrophy 9, Optic atrophy 9 |
| RS2066663117 |
COL4A5
|
Health Risk |
Pathogenic |
Alport syndrome, Alport syndrome |
| RS2066718 |
ABCA1
|
Health Risk |
Conflicting classifications of pathogenicity |
Tangier disease, Hypoalphalipoproteinemia |
| RS2066733 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary cancer-predisposing syndrome, Neurofibromatosis |
| RS2066734214 |
COL4A5
|
Health Risk |
Likely pathogenic |
— |
| RS2066735315 |
COL4A5
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2066736770 |
COL4A5
|
Health Risk |
Pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2066736944 |
COL4A5
|
Health Risk |
Likely pathogenic |
Nephrotic syndrome, Nephrotic syndrome |
| RS2066749314 |
TTN
|
Health Risk |
Likely pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2J, Dilated cardiomyopathy 1G |
| RS2066765994 |
PCCA
|
Health Risk |
Pathogenic |
Propionic acidemia, Propionic acidemia |
| RS2066766926 |
PCCA
|
Health Risk |
Likely pathogenic |
Propionic acidemia, Propionic acidemia |
| RS2066773116 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066785062 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066785267 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066785835 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066785949 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066786100 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066786672 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066787009 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066787606 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066802091 |
RPGR
|
Health Risk |
Conflicting classifications of pathogenicity |
Primary ciliary dyskinesia, Retinal dystrophy |
| RS2066827 |
CDKN1B
|
Health Risk |
Conflicting classifications of pathogenicity |
Multiple endocrine neoplasia type 4, Hereditary cancer-predisposing syndrome |
| RS2066831 |
PTCH1
|
Health Risk |
Pathogenic |
— |
| RS2066834 |
PTCH1
|
Health Risk |
Conflicting classifications of pathogenicity |
Gorlin syndrome, Hereditary cancer-predisposing syndrome |
| RS2066844 |
NOD2
|
Health Risk |
Conflicting classifications of pathogenicity; association |
Blau syndrome, Yao syndrome |
| RS2066845 |
NOD2
|
Health Risk |
Conflicting classifications of pathogenicity |
Blau syndrome, Yao syndrome |
| RS2066847 |
NOD2
|
Health Risk |
Conflicting classifications of pathogenicity; association |
Yao syndrome, Blau syndrome |
| RS2066859618 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2066861383 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2066862 |
FGG
|
Health Risk |
Conflicting classifications of pathogenicity |
FIBRINOGEN PARIS 1, Congenital afibrinogenemia |
| RS2066864084 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2066874267 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066874419 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066874810 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066876397 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066876556 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066877456 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066877516 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066877587 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066879614 |
TCTN1
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2066881864 |
HUWE1
|
Health Risk |
Likely pathogenic |
Intellectual disability, Intellectual disability |
| RS2066882139 |
HLCS
|
Health Risk |
Pathogenic/Likely pathogenic |
Holocarboxylase synthetase deficiency, Holocarboxylase synthetase deficiency |
| RS2066894484 |
HLCS
|
Health Risk |
Likely pathogenic |
Holocarboxylase synthetase deficiency, Holocarboxylase synthetase deficiency |
| RS2066897889 |
HLCS
|
Health Risk |
Likely pathogenic |
Holocarboxylase synthetase deficiency, Holocarboxylase synthetase deficiency |
| RS2066899099 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2066901407 |
COL4A5
|
Health Risk |
Pathogenic |
— |
| RS2066903607 |
HLCS
|
Health Risk |
Pathogenic/Likely pathogenic |
Holocarboxylase synthetase deficiency, Holocarboxylase synthetase deficiency |
| RS2066904707 |
MECP2
|
Health Risk |
Pathogenic |
— |
| RS2066907057 |
MECP2
|
Health Risk |
Conflicting classifications of pathogenicity |
Rett syndrome, Rett syndrome |
| RS2066910297 |
GPHN
|
Health Risk |
Likely pathogenic |
Seizure, Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C |
| RS2066914171 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2066915159 |
NF2
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 2 |
| RS2066926774 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066927450 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066927581 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066928095 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066928367 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066928784 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066929440 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066942076 |
HLCS
|
Health Risk |
Likely pathogenic |
Holocarboxylase synthetase deficiency, Holocarboxylase synthetase deficiency |
| RS2066942173 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066942649 |
HLCS
|
Health Risk |
Pathogenic |
Holocarboxylase synthetase deficiency, Holocarboxylase synthetase deficiency |
| RS2066961306 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066961890 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066962321 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066962353 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066962518 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066962730 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066964073 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066964219 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066989409 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066989481 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066990036 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066990429 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066990838 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066990906 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066990975 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066991605 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066991676 |
NF1
|
Health Risk |
Pathogenic |
— |
| RS2066991740 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2066992127 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066992207 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066992658 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066993468 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2066993840 |
NF1
|
Health Risk |
Pathogenic |
Hereditary cancer-predisposing syndrome, Cardiovascular phenotype |
| RS2066993930 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2066994053 |
NF1
|
Health Risk |
Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2067016221 |
CASK
|
Health Risk |
Likely pathogenic |
Syndromic X-linked intellectual disability Najm type, Syndromic X-linked intellectual disability Najm type |
| RS2067016341 |
CASK
|
Health Risk |
Pathogenic |
— |
| RS2067016459 |
CASK
|
Health Risk |
Conflicting classifications of pathogenicity |
Intellectual disability, CASK-related |
| RS2067016480 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2067016517 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2067017409 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2067017511 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2067018146 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2067018186 |
COL4A5
|
Health Risk |
Likely pathogenic |
X-linked Alport syndrome, X-linked Alport syndrome |
| RS2067018223 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |